JPH11343244A - Oral composition - Google Patents
Oral compositionInfo
- Publication number
- JPH11343244A JPH11343244A JP11073131A JP7313199A JPH11343244A JP H11343244 A JPH11343244 A JP H11343244A JP 11073131 A JP11073131 A JP 11073131A JP 7313199 A JP7313199 A JP 7313199A JP H11343244 A JPH11343244 A JP H11343244A
- Authority
- JP
- Japan
- Prior art keywords
- muirapuama
- taurine
- day
- ulcer
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 241000340987 Ptychopetalum olacoides Species 0.000 claims abstract description 20
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 230000002496 gastric effect Effects 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 9
- 201000005917 gastric ulcer Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 208000007882 Gastritis Diseases 0.000 abstract description 7
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 6
- 241000221014 Olacaceae Species 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- -1 defoamers Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003048 aphrodisiac agent Substances 0.000 description 2
- 230000002509 aphrodisiac effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019265 sodium DL-malate Nutrition 0.000 description 2
- 239000001394 sodium malate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000018893 Cercis canadensis var canadensis Nutrition 0.000 description 1
- 240000000024 Cercis siliquastrum Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017753 Gastric atony Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001061526 Pluteus cervinus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- VEHZBMGMMPZMRJ-UHFFFAOYSA-N acetic acid;2-(diethylamino)acetic acid Chemical compound CC(O)=O.CCN(CC)CC(O)=O VEHZBMGMMPZMRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940083256 peripheral vasodilators nicotinic acid and derivative Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、疲労、ストレス、
虚弱体質等による胃炎・胃潰瘍および十二指腸潰瘍をは
じめとする胃粘膜障害を治療または予防することができ
る安全な薬剤に関する。The present invention relates to fatigue, stress,
The present invention relates to a safe drug capable of treating or preventing gastric mucosal disorders such as gastritis, gastric ulcer, and duodenal ulcer due to a weak constitution.
【０００２】[0002]
【従来の技術】従来、胃腸障害を改善するため様々な薬
剤が開発されているが、現代社会においては、特にスト
レスに伴う胃腸障害を改善するための、より安全性の高
い成分が望まれている。そこで、副作用がほとんどなく
大量投与が可能であるタウリンを有効成分とする胃粘膜
障害治療剤が提案されている（特開平３−８１２１９
号）。2. Description of the Related Art Conventionally, various drugs have been developed to improve gastrointestinal disorders. In the modern society, however, a more safe ingredient for improving gastrointestinal disorders caused by stress is desired. I have. Therefore, a therapeutic agent for gastric mucosal disorder containing taurine as an active ingredient, which has almost no side effects and can be administered in large amounts, has been proposed (JP-A-3-81219).
issue).
【０００３】一方、ムイラプアマは、ブラジル・アマゾ
ン川流域に生育するボロボロノキ科(Olacaceae)植物のP
tychopetalum Olacoides、Ptychopetlum Uncinatum、Li
riosma Ovataの根を基源とする薬用植物で、古来、催
淫、強壮、強精薬として、または生殖器系、中枢神経
系、消化器系、循環器系に対する作用を期待して経験的
に使用され、民間で伝承されてきた。特に、ムイラプア
マ酒やその煎液は主に催淫、強壮、強精作用を期待して
利用されてきた。また、消化器系に対する作用では、消
化不良、食欲不振、胃弱、下痢、赤痢、十二指腸鉤虫症
に有用であることが文献等に記載されているが、胃炎・
胃潰瘍および十二指腸潰瘍をはじめとする胃粘膜障害に
対する作用は未だ報告されていない。[0003] On the other hand, Muirapuama is, P of Boroboronoki Department (Olacaceae) plants growing in Brazil Amazon Basin
tychopetalum Olacoides , Ptychopetlum Uncinatum , Li
Medicinal plant based on the roots of riosma Ovata , used anciently, as an aphrodisiac, tonic, tonic, or empirically for its effects on the reproductive, central nervous, digestive, and circulatory systems Has been handed down in the private sector. In particular, muirapuama liquor and its decoction have been used mainly with the expectation of aphrodisiac, tonic and tonic effects. In terms of its effects on the digestive system, it is described in literatures as being useful for indigestion, anorexia, weak stomach, diarrhea, dysentery, and duodenal hookworm.
No effect has been reported on gastric mucosal disorders including gastric ulcer and duodenal ulcer.
【０００４】消化不良、胃弱、食欲不振は多くの場合、
胃壁の緊張もしくは胃蠕動運動が極端に低下した状態の
胃アトニーや、固有胃腺の萎縮がその本態である慢性胃
炎時に多く見られ、さらに、キャンピロバクター・ピロ
リまたはヘリコバクター・ピロリなどの細菌感染による
急性胃炎・胃潰瘍は胃酸分泌の低下がその原因といわれ
ている。したがって、精神的または肉体的緊張・精神的
葛藤、外傷、重篤疾患、大手術などの場合のストレスに
よる、胃酸分泌の亢進、蠕動運動の亢進または防御因子
の低下が発症メカニズムとされる消化性潰瘍とは本質的
に異なる病態といえる。[0004] Indigestion, weak stomach and anorexia are often
Gastric atony with extremely reduced gastric wall tone or gastric peristalsis, or atrophy of the proper gastric glands is common during chronic gastritis, the main cause of which is caused by bacterial infection such as Campylobacter pylori or Helicobacter pylori. It is said that acute gastritis and gastric ulcer are caused by decreased gastric acid secretion. Therefore, gastric acid secretion, increased peristalsis, or reduced digestive factors are considered as the mechanism of development due to stress in the case of mental or physical tension / mental conflict, trauma, serious illness, major surgery, etc. It can be said that the condition is essentially different from ulcer.
【０００５】[0005]
【発明が解決しようとする課題】本発明の目的は、長期
間服用しても安全かつ効果的な胃炎・胃潰瘍および十二
指腸潰瘍をはじめとする胃粘膜障害を予防または治療す
る経口用組成物を提供することである。An object of the present invention is to provide an oral composition for preventing or treating gastric mucosal disorders such as gastritis, gastric ulcer and duodenal ulcer which is safe and effective even if taken for a long period of time. It is to be.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、前記目的
を達成するために鋭意研究を行った結果、ムイラプアマ
エキスが胃潰瘍を予防または治療すること、また、タウ
リンと組み合わせることにより、その作用がさらに増強
されることを見いだし、本発明を完成した。すなわち、
本発明はムイラプアマまたはムイラプアマとタウリンと
組み合わせて含有することを特徴とする胃炎・胃潰瘍お
よび十二指腸潰瘍をはじめとする胃粘膜障害を予防また
は治療する経口用組成物である。Means for Solving the Problems The present inventors have conducted intensive studies in order to achieve the above object, and as a result, it has been found that muirapuama extract prevents or treats gastric ulcer, and its effect by combining with taurine. Was further enhanced, and the present invention was completed. That is,
The present invention is an oral composition for preventing or treating gastric mucosal disorders such as gastritis / gastric ulcer and duodenal ulcer, which is characterized by containing muirapuama or muirapuama in combination with taurine.
【０００７】本発明に用いるムイラプアマの基源植物
は、ブラジル・アマゾン川流域に生育するボロボロノキ
科（Olacaceae）の低木で、Ptychopetelum Olacoidesの
他、Ptychopetalum Uncinatum、Liriosma Ovateがあ
り、好ましくは、Ptychopetelum Olacoidesであるが、P
tychopetalum Uncinatum、Liriosma Ovateも用いること
ができる。本発明ではこれらの基源植物の根が用いられ
る。[0007] radical source plants Muirapuama used in the present invention is a shrub Boroboronoki family which grows in Brazil Amazon Basin (Olacaceae), other Ptychopetelum Olacoides, Ptychopetalum Uncinatum, there is Liriosma OVATE, preferably at Ptychopetelum Olacoides Yes, but P
tychopetalum Uncinatum and Liriosma Ovate can also be used. In the present invention, the roots of these base plants are used.
【０００８】本発明におけるムイラプアマの有効投与量
は、原生薬換算量として成人で１日１０ｍｇ〜５０００
ｍｇであり、好ましくは１００ｍｇ〜３０００ｍｇであ
る。また、タウリンの有効投与量は、成人で１日１００
ｍｇ〜５０００ｍｇであり、好ましくは５００ｍｇ〜３
０００ｍｇである。また両者を配合する場合にはムイラ
プアマ１重量部に対してタウリン０．０２重量部〜５０
重量部、好ましくは０．１５重量部〜３０重量部であ
る。In the present invention, the effective dose of muirapuama is 10 mg to 5000 mg / day for an adult in terms of a crude drug equivalent.
mg, preferably 100 mg to 3000 mg. The effective dose of taurine is 100 per day for adults.
mg to 5000 mg, preferably 500 mg to 3 mg.
000 mg. When both are blended, taurine 0.02 parts by weight to 50 parts by weight per 1 part by weight of muirapuama
Parts by weight, preferably 0.15 to 30 parts by weight.
【０００９】本発明については、本成分に影響を与えな
い程度で、ビタミンＢ１、ビタミンＢ２、ビタミンＢ
６、ビタミンＢ１２、ビオチン、カルニチン、パントテ
ン酸およびニコチン酸とその誘導体などの水溶性ビタミ
ン、五味子、海狗腎、山茱萸、杜仲、菟絲子、蛇床子、
肉▲ジュ▼蓉、山薬、冬虫夏草、鹿茸、地黄、茯苓、桂
皮、枸杞子、当帰、甘草、黄精、黄耆、柴胡、生姜、大
棗、淫羊▲カク▼、反鼻、人参、山奈、芍薬、ホップ、
大黄、木香、苦参、石菖蒲、阿仙薬、アロエ、赤芽柏、
揚梅皮、烏梅、蒼朮、白朮、厚朴、黄▲ゴン▼などの生
薬を配合することができる。In the present invention, vitamin B1, vitamin B2, vitamin B
6. Vitamin B12, biotin, carnitine, water-soluble vitamins such as pantothenic acid and nicotinic acid and derivatives thereof, omimikomi, kaigu kidney, sanshuyu, tochu, toutiko, snakebed,
Meat ▲ Ju ▼ Rong, Sanpo, Cordyceps, Deer mushroom, Jihuang, Bukuryo, Cinnamon bark, Gugiko, Toki, Licorice, Yellow sperm, Astragalus, Saiko, Ginger, Daijutsu, Inferior sheep ▲ Kaku ▼, Anti-nose, Ginseng , Yamana, peony, hops,
Rhubarb, wood incense, ginseng, iris, asenyaku, aloe, red bud,
Crude drugs such as plum bark, ume, sojutsu, shirojutsu, koboku, and yellow gon are available.
【００１０】本発明の有効成分である経口用組成物は、
そのままあるいは必要に応じて他の添加剤、例えば、賦
形剤、ｐＨ調整剤、清涼化剤、懸濁化剤、消泡剤、粘稠
剤、溶解補助剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、
コーティング剤、着色剤、矯味矯臭剤、界面活性剤、可
塑剤、香料などを混合して常法により、液剤、錠剤、顆
粒剤、散剤、カプセル剤、ドライシロップ剤、チュアブ
ル錠などの経口製剤とすることができる。The oral composition which is an active ingredient of the present invention comprises:
As is or as needed, other additives such as excipients, pH adjusters, fresheners, suspending agents, defoamers, thickeners, solubilizers, disintegrants, binders, lubricants Agents, antioxidants,
Oral preparations such as liquids, tablets, granules, powders, capsules, dry syrups and chewable tablets are prepared by mixing a coating agent, a colorant, a flavoring agent, a surfactant, a plasticizer, a fragrance and the like by a conventional method. be able to.
【００１１】賦形剤としては、例えばＤ−ソルビトー
ル、Ｄ−マンニトール、キシリトールなどの糖アルコー
ル、ブドウ糖、白糖、乳糖、果糖などの糖類、結晶セル
ロース、カルメロースナトリウム、リン酸水素カルシウ
ム、コムギデンプン、コメデンプン、トウモロコシデン
プン、バレイショデンプン、デキストリン、β−シクロ
デキストリン、軽質無水ケイ酸、酸化チタン、メタケイ
酸アルミン酸マグネシウム、などがあげられる。Examples of the excipient include sugar alcohols such as D-sorbitol, D-mannitol and xylitol, sugars such as glucose, sucrose, lactose and fructose, crystalline cellulose, carmellose sodium, calcium hydrogen phosphate, wheat starch, Rice starch, corn starch, potato starch, dextrin, β-cyclodextrin, light anhydrous silicic acid, titanium oxide, magnesium aluminate metasilicate, and the like.
【００１２】ｐＨ調整剤としては、例えばクエン酸、リ
ンゴ酸、リン酸水素ナトリウム、リン酸二水素カリウム
などがあげられる。清涼化剤としては、例えばｌ−メン
トール、ハッカ水などがあげられる。懸濁化剤として
は、例えばカオリン、カルメロースナトリウム、キサン
タンガム、メチルセルロース、トラガントなどがあげら
れる。消泡剤としては、例えばジメチルポリシロキサ
ン、シリコン消泡剤などがあげられる。粘稠剤として
は、例えばキサンタンガム、トラガント、メチルセルロ
ース、デキストリンなどがあげられる。溶解補助剤とし
ては、例えばエタノール、ショ糖脂肪酸エステル、マク
ロゴールなどがあげられる。崩壊剤としては、例えば低
置換度ヒドロキシプロピルセルロース、カルボキシメチ
ルセルロースカルシウム、クロスカルメロースナトリウ
ム、ヒドロキシプロピルスターチ、部分アルファー化デ
ンプンなどがあげられる。Examples of the pH adjuster include citric acid, malic acid, sodium hydrogen phosphate, potassium dihydrogen phosphate and the like. Examples of the cooling agent include l-menthol, peppermint water and the like. Examples of the suspending agent include kaolin, carmellose sodium, xanthan gum, methylcellulose, tragacanth and the like. Examples of the antifoaming agent include dimethylpolysiloxane and silicone antifoaming agent. Examples of the thickener include xanthan gum, tragacanth, methylcellulose, dextrin and the like. Examples of the solubilizing agent include ethanol, sucrose fatty acid ester, macrogol and the like. Disintegrators include, for example, low-substituted hydroxypropylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, hydroxypropyl starch, partially pregelatinized starch and the like.
【００１３】結合剤としては、例えばメチルセルロー
ス、ヒドロキシプロピルセルロース、ヒドロキシプロピ
ルメチルセルロース、ポリビニールピロリドン、ゼラチ
ン、アラビアゴム、エチルセルロース、ポリビニルアル
コール、プルラン、アルファー化デンプン、カンテン、
トラガント、アルギン酸ナトリウム、アルギン酸プロピ
レングリコールエステルなどがあげられる。Examples of the binder include methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethylcellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar,
Tragacanth, sodium alginate, propylene glycol alginate and the like.
【００１４】滑沢剤としては、例えばステアリン酸、ス
テアリン酸マグネシウム、ステアリン酸カルシウム、ス
テアリン酸ポリオキシル、セタノール、タルク、硬化
油、ショ糖脂肪酸エステル、ジメチルポリシロキサン、
ミツロウ、サラシミツロウなどがあげられる。抗酸化剤
としては、例えばジブチルヒドロキシトルエン（ＢＨ
Ｔ）、没食子酸プロピル、ブチルヒドロキシアニソール
（ＢＨＡ）、トコフェロール、クエン酸などがあげられ
る。Examples of the lubricant include stearic acid, magnesium stearate, calcium stearate, polyoxyl stearate, cetanol, talc, hydrogenated oil, sucrose fatty acid ester, dimethylpolysiloxane,
Beeswax, beeswax and the like. As an antioxidant, for example, dibutylhydroxytoluene (BH
T), propyl gallate, butylhydroxyanisole (BHA), tocopherol, citric acid and the like.
【００１５】コーティング剤としては、例えばヒドロキ
シプロピルメチルセルロース、ヒドロキシプロピルセル
ロース、メチルセルロース、エチルセルロース、ヒドロ
キシプロピルメチルセルロースフタレート、ヒドロキシ
プロピルメチルセルロースアセテートサクシネート、カ
ルボキシメチルエチルセルロース、酢酸フタル酸セルロ
ース、ポリビニルアセタールジエチルアミノアセテー
ト、アミノアルキルメタアクリレートコポリマー、メタ
アクリル酸コポリマー、ポリビニルアセテートジエチル
アミノアセテート、セラックなどがあげられる。Examples of the coating agent include hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, polyvinyl acetal diethylaminoacetate, aminoalkyl meta Acrylate copolymer, methacrylic acid copolymer, polyvinyl acetate diethylaminoacetate, shellac and the like can be mentioned.
【００１６】着色剤としては、例えばウコン抽出液、リ
ボフラビン、酸化チタン、カロチン液などがあげられ
る。矯味剤としては、例えばアスパルテーム、アスコル
ビン酸、ステビア、メントール、カンゾウ粗エキス、単
シロップなどがあげられる。Examples of the coloring agent include turmeric extract, riboflavin, titanium oxide, carotene solution and the like. Examples of the flavoring agent include aspartame, ascorbic acid, stevia, menthol, licorice crude extract, simple syrup and the like.
【００１７】界面活性剤としては、例えばポリオキシエ
チレン硬化ヒマシ油、モノステアリン酸グリセリン、モ
ノステアリン酸ソルビタン、モノラウリン酸ソルビタ
ン、ポリオキシエチレンポリオキシプロピレン、ポリソ
ルベート類、ラウリル硫酸ナトリウム、マクロゴール
類、ショ糖脂肪酸エステルなどがあげられる。可塑剤と
しては、例えばクエン酸トリエチル、ポリエチレングリ
コール、トリアセチン、セタノールなどがあげられる。Examples of the surfactant include polyoxyethylene hydrogenated castor oil, glycerin monostearate, sorbitan monostearate, sorbitan monolaurate, polyoxyethylene polyoxypropylene, polysorbates, sodium lauryl sulfate, macrogol, Sugar fatty acid esters and the like. Examples of the plasticizer include triethyl citrate, polyethylene glycol, triacetin, cetanol and the like.
【００１８】[0018]
【発明の効果】本発明により、肉体疲労、精神疲労、ス
トレスおよび虚弱体質等による胃炎・胃潰瘍および十二
指腸潰瘍をはじめとする胃粘膜障害を治療あるいは予防
することができる。According to the present invention, gastric mucosal disorders such as gastritis / gastric ulcer and duodenal ulcer due to physical fatigue, mental fatigue, stress and weak constitution can be treated or prevented.
【００１９】[0019]
【実施例】以下に実施例及び試験例を挙げ、本発明を具
体的に説明する。The present invention will be specifically described below with reference to examples and test examples.
【００２０】 実施例１ （成分） 配合量 ムイラプアマ ３０００ｍｇ（原生薬換算量として） ショ糖 ２８００ｍｇ キシリトール １０００ｍｇ 安息香酸 １２ｍｇ クエン酸 １００ｍｇ リンゴ酸ナトリウム ４０ｍｇ ポリグリセリン脂肪酸エステル ８ｍｇ ポリオキシエチレン硬化ヒマシ油 ８ｍｇ 精製水 全２０ｍｌ 上記成分を攪拌し、均一に溶解させ内服液剤を調製した。Example 1 (Components) Compounding amount Muirapuama 3000 mg (as crude drug equivalent) Sucrose 2800 mg Xylitol 1000 mg Benzoic acid 12 mg Citric acid 100 mg Sodium malate 40 mg Polyglycerin fatty acid ester 8 mg Polyoxyethylene hydrogenated castor oil 8 mg Purified water All 20 ml The above components were stirred and uniformly dissolved to prepare an oral liquid preparation.
【００２１】 実施例２ （成分） 配合量 ムイラプアマ ３０００ｍｇ（原生薬換算量として） タウリン ２５００ｍｇ ショ糖 ２８００ｍｇ Ｄ−ソルビット １０００ｍｇ 安息香酸 １２ｍｇ クエン酸 １００ｍｇ リンゴ酸ナトリウム ４０ｍｇ ポリグリセリン脂肪酸エステル ８ｍｇ ポリオキシエチレン硬化ヒマシ油 ８ｍｇ 精製水 ２０ｍｌ 上記成分を攪拌し、均一に溶解させ内服液剤を調製した 実施例３ （成分） 配合量 ムイラプアマ ３０００ｍｇ（原生薬換算量として） タウリン ２５００ｍｇ 乳糖 ５００ｍｇ トウモロコシデンプン ２４５ｍｇ メタケイ酸アルミン酸マグネシウム ３２．５ｍｇ 軽質無水ケイ酸 ３７．５ｍｇ 低置換度ヒドロキシプロピルセルロース ５０ｍｇ 上記成分を混合した後、精製水適量を添加して練合・造
粒・乾燥して粒状物を得た。この粒状物にステアリン酸
マグネシウム、硬化油および香料を適宜加えて打錠し、
錠剤５錠を調製した。Example 2 (Ingredients) Compounding amount Muirapuama 3000 mg (as crude drug equivalent) Taurine 2500 mg Sucrose 2800 mg D-Sorbit 1000 mg Benzoic acid 12 mg Citric acid 100 mg Sodium malate 40 mg Polyglycerin fatty acid ester 8 mg Polyoxyethylene hydrogenated castor oil 8 mg Purified water 20 ml The above components were stirred and uniformly dissolved to prepare a liquid for internal use. Example 3 (Components) Compounding amount Muirapuama 3000 mg (as equivalent to crude drug) Taurine 2500 mg Lactose 500 mg Maize starch 245 mg Magnesium aluminate metasilicate 32. 5mg Light silicic anhydride 37.5mg Low-substituted hydroxypropylcellulose 50mg After mixing the above components, add an appropriate amount of purified water and knead / granulate / To obtain a granulate with 燥. Magnesium stearate, hydrogenated oil and fragrance are appropriately added to the granules and tableted,
Five tablets were prepared.
【００２２】実施例４ 実施例３にさらにアスパルテーム１０００ｍｇを加え
て、同様にして粒状物を得た。この粒状物にステアリン
酸マグネシウム、硬化ヒマシ油を適宜加えて均一に混合
し、分包剤１０包を調製した。Example 4 To Example 3, 1000 mg of aspartame was further added, and a granular product was obtained in the same manner. Magnesium stearate and hydrogenated castor oil were appropriately added to the granules and uniformly mixed to prepare 10 sachets.
【００２３】試験例１ Wistar系雄性ラット（約８週齢、体重約２４０g、絶食
後体重２００〜２２０g）をＡ、ＢおよびＣ群に分けて
用い、Ａ群にムイラプアマ（３０００ｍｇ／ｋｇ）、Ｂ
群にムイラプアマ（３０００ｍｇ／ｋｇ）＋タウリン
（２５００ｍｇ／ｋｇ）およびＣ（コントロール）群に
は水を経口投与し、水槽（バケツなど）中で７時間水浸
することにより胃潰瘍を惹起した。ストレス負荷終了
後、直ちにラットを断頭致死させ、胃を摘出し、幽門を
クリップにて結紮した後、１％ホルマリン液７〜１０ml
を噴門部から胃内に注入した。注入後、直ちに、液が漏
れないように噴門をクッリプにて結紮した後、１％ホル
マリン液中で、１０分間、胃を固定した。洗浄後、大弯
にそって大きく切り開き、形を整え、プラスチック板上
に張り付け、実体顕微鏡下で潰瘍の面積（あるいは個
数）を測定した。なお、ラットは、各群７匹とした。Test Example 1 Male Wistar rats (about 8 weeks old, weighing about 240 g, weighing 200-220 g after fasting) were divided into groups A, B and C, and muirapuama (3000 mg / kg) and B were used in group A.
Water was orally administered to the muirapuama (3000 mg / kg) + taurine (2500 mg / kg) and C (control) groups, and gastric ulcer was induced by immersion in a water tank (bucket or the like) for 7 hours. Immediately after the end of the stress load, the rat was sacrificed by decapitation, the stomach was removed, the pylorus was ligated with a clip, and then 7 to 10 ml of 1% formalin solution.
Was injected into the stomach through the cardia. Immediately after the injection, the cardia was ligated with a clip so that the liquid did not leak, and then the stomach was fixed in 1% formalin solution for 10 minutes. After washing, the ulcer was cut open widely along the greater curvature, shaped, pasted on a plastic plate, and the area (or number) of ulcers was measured under a stereoscopic microscope. In addition, there were seven rats in each group.
【００２４】結果 水浸ストレスを負荷したラットのＡ群、Ｂ群およびＣ
（コントロール）群における潰瘍計数を表１に示す。表
１から明らかなように、水浸拘束による潰瘍形成に対し
てＡ群では５３．０％、Ｂ群では７３．８％とその抑制
率がさらに増強された。Results Groups A, B and C of rats subjected to water immersion stress
Table 1 shows the ulcer counts in the (control) group. As is clear from Table 1, the suppression rate of ulcer formation due to water immersion restraint was further enhanced to 53.0% in Group A and 73.8% in Group B.
【００２５】[0025]
【表１】 [Table 1]
フロントページの続き (72)発明者 角田 健司 東京都豊島区高田３丁目24番１号 大正製 薬株式社内Continued on the front page (72) Inventor Kenji Tsunoda 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (2)
ことを特徴とする胃粘膜障害を治療または予防する経口
用組成物。[1] An oral composition for treating or preventing gastric mucosal injury, comprising muirapuama or an extract thereof.
る請求項１記載の組成物。2. The composition according to claim 1, further comprising taurine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11073131A JPH11343244A (en) | 1998-03-30 | 1999-03-18 | Oral composition |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8328998 | 1998-03-30 | ||
| JP10-83289 | 1998-03-30 | ||
| JP11073131A JPH11343244A (en) | 1998-03-30 | 1999-03-18 | Oral composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11343244A true JPH11343244A (en) | 1999-12-14 |
Family
ID=26414286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11073131A Pending JPH11343244A (en) | 1998-03-30 | 1999-03-18 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11343244A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531557A (en) * | 2002-05-17 | 2005-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Use of effective compounds as selective opiate receptor modulators |
| JP2014040393A (en) * | 2012-08-23 | 2014-03-06 | Taisho Pharmaceutical Co Ltd | Gene expression regulating agent |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0381219A (en) * | 1989-08-24 | 1991-04-05 | Motoyasu Murakami | Remedy for gastric mucosal disorder |
| WO1994002160A1 (en) * | 1992-07-20 | 1994-02-03 | Taisho Pharmaceutical Co., Ltd. | Tonic |
-
1999
- 1999-03-18 JP JP11073131A patent/JPH11343244A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0381219A (en) * | 1989-08-24 | 1991-04-05 | Motoyasu Murakami | Remedy for gastric mucosal disorder |
| WO1994002160A1 (en) * | 1992-07-20 | 1994-02-03 | Taisho Pharmaceutical Co., Ltd. | Tonic |
Non-Patent Citations (2)
| Title |
|---|
| JPN6009043141, 華西医科大学学報, 1992, Ｖｏｌ．２３ Ｎｏ．１, ｐｐ．９８−１０１ * |
| JPN6009043143, 生薬学雑誌, 1979, Ｖｏｌ．３３ Ｎｏ．２, ｐｐ．５７−６４ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531557A (en) * | 2002-05-17 | 2005-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Use of effective compounds as selective opiate receptor modulators |
| JP2014040393A (en) * | 2012-08-23 | 2014-03-06 | Taisho Pharmaceutical Co Ltd | Gene expression regulating agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002096406A1 (en) | Medicinal compositions | |
| EP1865929A2 (en) | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| JPH11343244A (en) | Oral composition | |
| US4975423A (en) | Inhibition of tumor development | |
| JP3612729B2 (en) | Nourishing tonic | |
| JPH09227394A (en) | Composition for oral administration | |
| WO2014007549A2 (en) | Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same | |
| WO2017020862A1 (en) | Application of polygonum capitatum composition in treating gastritis | |
| WO2016208926A1 (en) | Pharmaceutical composition comprising isopropanol extract of artemisiae argyi folium | |
| JP2010013364A (en) | Preventive or ameliorating agent for hyperuricemia | |
| WO2019004626A1 (en) | Composition for preventing or treating menopausal syndrome, containing medicinal herb extract as active ingredient | |
| NZ212301A (en) | Pharmaceutical compositions containing peroxydiphosphoric acid derivatives | |
| JP2681085B2 (en) | Gastritis treatment | |
| US20220370492A1 (en) | Pharmaceutical composition for reducing protein bound uremic toxins | |
| JP5272384B2 (en) | Treatment for oral mucosal disease | |
| WO2017052172A1 (en) | Novel use of alcohol extract of taraxaci herba | |
| JP2007145731A (en) | Pharmaceutical preparation for oral administration having stegnotic effect | |
| JP2010173980A (en) | Agent for preventing or improving hyperuricemia | |
| KR20170026242A (en) | Pharmaceutical composition for treatment or prevention of liver disease | |
| KR20000019869A (en) | Composition comprising extract of seed of carthamus tinctorius l. for promoting regeneration of hard tissues | |
| WO2024018374A1 (en) | A pharmaceutical composition providing mucolytic effect | |
| TWI527828B (en) | A novel triterpenoid and uses thereof | |
| CN104958274B (en) | Antrodia camphorata effervescent tablet | |
| EA007488B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060213 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091021 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100316 |